Search Results

There are 16895 results for: content related to: Recent topics related to nephrogenic systemic fibrosis associated with gadolinium-based contrast agents

  1. Nephrogenic systemic fibrosis and the role of gadolinium contrast media

    Journal of Medical Imaging and Radiation Oncology

    Volume 52, Issue 4, August 2008, Pages: 339–350, AJ Van Der Molen

    Version of Record online : 16 SEP 2008, DOI: 10.1111/j.1440-1673.2008.01965.x

  2. Risk of nephrogenic systemic fibrosis is low in patients with chronic liver disease exposed to gadolinium-based contrast agents

    Journal of Magnetic Resonance Imaging

    Volume 41, Issue 5, May 2015, Pages: 1259–1267, Emmanuil Smorodinsky, David S. Ansdell, Zeke W. Foster, Sameer M. Mazhar, Irene Cruite, Tanya Wolfson, Sebastian B. Sugay, Gabriella Iussich, Masoud Shiehmorteza, Yuko Kono, Alexander Kuo and Claude B. Sirlin

    Version of Record online : 9 MAY 2014, DOI: 10.1002/jmri.24650

  3. Gadolinium and Nephrogenic Systemic Fibrosis: Have We Overreacted?

    Seminars in Dialysis

    Volume 24, Issue 5, September/October 2011, Pages: 480–486, Jeffrey G. Penfield and Robert F. Reilly

    Version of Record online : 13 SEP 2011, DOI: 10.1111/j.1525-139X.2011.00945.x

  4. Nephrogenic systemic fibrosis: A case report and review on Japanese patients

    The Journal of Dermatology

    Volume 39, Issue 5, May 2012, Pages: 449–453, Yuka MATSUMOTO, Yoshihiko MITSUHASHI, Fumiko MONMA, Masakazu KAWAGUCHI, Tamio SUZUKI, Chie MIYABE, Atsuyuki IGARASHI and Ryoji TSUBOI

    Version of Record online : 31 OCT 2011, DOI: 10.1111/j.1346-8138.2011.01407.x

  5. You have free access to this content
    Hyperphosphataemia sensitizes renally impaired rats to the profibrotic effects of gadodiamide

    British Journal of Pharmacology

    Volume 165, Issue 4b, February 2012, Pages: 1151–1162, N Fretellier, JM Idée, P Bruneval, S Guerret, F Daubiné, G Jestin, C Factor, N Poveda, A Dencausse, F Massicot, O Laprévote, C Mandet, N Bouzian, M Port and C Corot

    Version of Record online : 26 JAN 2012, DOI: 10.1111/j.1476-5381.2011.01585.x

  6. NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Patient Characteristics and Risk Factors for Nephrogenic Systemic Fibrosis Following Gadolinium Exposure

    Seminars in Dialysis

    Volume 21, Issue 2, March/April 2008, Pages: 135–139, Thomas Grobner and Friedrich C. Prischl

    Version of Record online : 23 JAN 2008, DOI: 10.1111/j.1525-139X.2007.00406.x

  7. You have free access to this content
    Validation of a Screening Instrument for Nephrogenic Systemic Fibrosis

    Arthritis Care & Research

    Volume 65, Issue 4, April 2013, Pages: 637–642, Xinaida Taligare Lima, Maria Beatrice Alora-Palli, Alexandra Boer Kimball and Jonathan Kay

    Version of Record online : 28 MAR 2013, DOI: 10.1002/acr.21877

  8. Nephrogenic Systemic Fibrosis and Gadolinium-Containing Radiological Contrast Agents: An Update

    Clinical Pharmacology & Therapeutics

    Volume 89, Issue 6, June 2011, Pages: 920–923, N Jalandhara, R Arora and V Batuman

    Version of Record online : 6 APR 2011, DOI: 10.1038/clpt.2010.346

  9. Time-dependent decrement of dermal gadolinium deposits and significant improvement of skin symptoms in a patient with nephrogenic systemic fibrosis after temporary renal failure

    Journal of Cutaneous Pathology

    Volume 40, Issue 11, November 2013, Pages: 935–944, Susanne G. Schäd, Peter Heitland, W. Nikolaus Kühn-Velten, Gerd E. Gross and Ludwig Jonas

    Version of Record online : 16 SEP 2013, DOI: 10.1111/cup.12214

  10. Nephrogenic systemic fibrosis, in patients with end-stage kidney disease on dialysis, in the greater Auckland region, from 2000–2006

    Nephrology

    Volume 16, Issue 2, February 2011, Pages: 243–248, JAMIE C KENDRICK-JONES, DAVID M VOSS and JANAK R DE ZOYSA

    Version of Record online : 27 JAN 2011, DOI: 10.1111/j.1440-1797.2010.01397.x

  11. Pathomechanisms of nephrogenic systemic fibrosis: new insights

    Clinical and Experimental Dermatology

    Volume 36, Issue 7, October 2011, Pages: 763–768, A. Gupta, M. K. Shamseddin and A. Khaira

    Version of Record online : 25 JUL 2011, DOI: 10.1111/j.1365-2230.2011.04136.x

  12. You have free access to this content
    Incidence of nephrogenic systemic fibrosis at Chinese PLA General Hospital

    Journal of Magnetic Resonance Imaging

    Volume 30, Issue 6, December 2009, Pages: 1309–1312, Zhitong Zou, Lin Ma and Hengjin Li

    Version of Record online : 24 NOV 2009, DOI: 10.1002/jmri.21769

  13. Gadolinium-Associated Nephrogenic Systemic Fibrosis in a 9-Year-Old Boy

    Pediatric Dermatology

    Volume 26, Issue 5, September/October 2009, Pages: 579–582, Clare Foss, Jeff K. Smith, Luis Ortiz, Coral Hanevold and Loretta Davis

    Version of Record online : 11 MAR 2009, DOI: 10.1111/j.1525-1470.2008.00802.x

  14. Nephrogenic systemic fibrosis: A nephrologist's perspective

    Hemodialysis International

    Volume 11, Issue s3, October 2007, Pages: S2–S6, Georges SAAB and Steven CHENG

    Version of Record online : 25 SEP 2007, DOI: 10.1111/j.1542-4758.2007.00222.x

  15. You have free access to this content
    Risk factors for NSF: A literature review

    Journal of Magnetic Resonance Imaging

    Volume 30, Issue 6, December 2009, Pages: 1298–1308, Martin R. Prince, Hong Lei Zhang, Giles H. Roditi, Tim Leiner and Walter Kucharczyk

    Version of Record online : 24 NOV 2009, DOI: 10.1002/jmri.21973

  16. You have free access to this content
    Induction of a type I interferon signature in normal human monocytes by gadolinium-based contrast agents: comparison of linear and macrocyclic agents

    Clinical & Experimental Immunology

    Volume 175, Issue 1, January 2014, Pages: 113–125, P. J. Wermuth and S. A. Jimenez

    Version of Record online : 3 DEC 2013, DOI: 10.1111/cei.12211

  17. A follow-up of four cases of nephrogenic systemic fibrosis: is gadolinium the specific trigger?

    British Journal of Dermatology

    Volume 158, Issue 6, June 2008, Pages: 1358–1362, M. Singh, A. Davenport, I. Clatworthy, J. Lewin, F. Deroide, V. Hubbard and M.H.A. Rustin

    Version of Record online : 20 MAR 2008, DOI: 10.1111/j.1365-2133.2008.08506.x

  18. You have free access to this content
    Gadolinium-based contrast agents and their potential role in the pathogenesis of nephrogenic systemic fibrosis: The role of excess ligand

    Journal of Magnetic Resonance Imaging

    Volume 27, Issue 5, May 2008, Pages: 955–962, Martin A. Sieber, Philipp Lengsfeld, Jakob Walter, Heiko Schirmer, Thomas Frenzel, Fred Siegmund, Hanns-Joachim Weinmann and Hubertus Pietsch

    Version of Record online : 18 APR 2008, DOI: 10.1002/jmri.21368

  19. Gadodiamide contrast agent ‘activates’ fibroblasts: a possible cause of nephrogenic systemic fibrosis

    The Journal of Pathology

    Volume 214, Issue 5, April 2008, Pages: 584–593, M Edward, JA Quinn, S Mukherjee, M-BV Jensen, AG Jardine, PB Mark and AD Burden

    Version of Record online : 11 DEC 2007, DOI: 10.1002/path.2311

  20. You have free access to this content
    Nephrogenic systemic fibrosis in liver disease: A systematic review

    Journal of Magnetic Resonance Imaging

    Volume 30, Issue 6, December 2009, Pages: 1313–1322, Sameer M. Mazhar, Masoud Shiehmorteza, Chad A. Kohl, Michael S. Middleton and Claude B. Sirlin

    Version of Record online : 24 NOV 2009, DOI: 10.1002/jmri.21983